Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19

NCT04836260 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Covid19
Immuno-Deficiency
Old Age; Debility

Interventions

DRUG: SARS-CoV-2 convalescent plasma

Sponsor

University Hospital, Geneva

Collaborators

[object Object]
[object Object]
[object Object]